Neurocrine Biosciences, Inc.
DE ˙ DB ˙ US64125C1099
134,65 € ↑0,30 (0,22%)
2026-06-03
DEL PRIS
SecurityDE:NB3 / Neurocrine Biosciences, Inc.
InstitutionAssetmark, Inc
Latest Disclosed Ownership17,277 shares
Latest Disclosed Value $ 2,276,072
Assetmark, Inc reports 10.58% decrease in ownership of NB3 / Neurocrine Biosciences, Inc.

On May 6, 2026 - Assetmark, Inc filed a 13F-HR form disclosing ownership of 17,277 shares of Neurocrine Biosciences, Inc. (DE:NB3) valued at $1,930,705 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 23, 2026 disclosing 19,321 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -10.58% during the quarter. The current value of the position is $2,326,348 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,277 -2,044 -10.58 2,276 -16.93 0.0046
2026-01-23 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,321 -915 -4.52 2,740 -3.52 0.0056
2025-11-06 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,236 -765 -3.64 2,841 7.62 0.0061
2025-08-04 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,001 2,045 10.79 2,640 25.91 0.0062
2025-05-06 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,956 -958 -4.81 2,097 -22.88 0.0058
2025-02-06 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,914 1,591 8.68 2,718 28.75 0.0074
2024-11-01 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,323 1,753 10.58 2,111 -7.45 0.0060
2024-08-13 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,570 4,460 36.83 2,281 36.59 0.0071
2024-05-07 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,110 -24,845 -67.23 1,670 -65.70 0.0054
2024-02-09 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 36,955 8,678 30.69 4,869 53.07 0.0176
2023-10-27 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,277 4,350 18.18 3,181 41.00 0.0127
2023-08-11 2023-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 23,927 4,151 20.99 2,256 12.74 0.0089
2023-05-05 2023-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 19,776 1,903 10.65 2,002 -6.23 0.0083
2023-02-10 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,873 1,471 8.97 2,135 22.50 0.0093
2022-11-01 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,402 2,929 21.74 1,742 32.67 0.0081
2022-08-03 2022-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 13,473 4,317 47.15 1,313 53.03 0.0059
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 9,156 4,093 80.84 858 99.07 0.0036
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 5,063 3,585 242.56 431 203.52 0.0018
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 1,478 1,478 142 0.0006
2019-11-13 2019-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 0 -12 -100.00 0 -100.00
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 12 2 20.00 1 0.00 0.0000
2019-05-14 2019-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 10 -18 -64.29 1 -50.00 0.0000
2019-02-13 2018-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 28 28 2 0.0000
2018-05-16 2018-03-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 0 -20 -100.00 0 -100.00
2018-02-13 2017-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 20 15 300.00 2 0.0000
2017-11-08 2017-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 5 5 0 0.0000
2017-09-14 2016-03-31 13F/A-1 NEUROCRINE BIOSCIENCES INC COM COM 64125C109 0 -15 -100.00 0 -100.00
2017-09-14 2015-12-31 13F/A-1 NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15 15 1 0.0000
2016-02-12 2015-12-31 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 15 15 1
2015-11-10 2015-09-30 13F NEUROCRINE BIOSCIENCES INC COM COM 64125C109 0 0 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.